Post-translational processing of beta-secretase in Alzheimer's disease
被引:23
作者:
Sidera, C
论文数: 0引用数: 0
h-index: 0
机构:
Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, EnglandUniv London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England
Sidera, C
[1
]
Parsons, R
论文数: 0引用数: 0
h-index: 0
机构:
Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, EnglandUniv London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England
Parsons, R
[1
]
Austen, B
论文数: 0引用数: 0
h-index: 0
机构:
Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, EnglandUniv London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England
Austen, B
[1
]
机构:
[1] Univ London St Georges Hosp, Sch Med, Dept Basic Med Sci, London SW17 0RE, England
Alzheimer's disease;
beta-secretase;
cholesterol;
glycosylation;
mass spectrometry;
palmitoylation;
statin;
D O I:
10.1002/pmic.200401185
中图分类号:
Q5 [生物化学];
学科分类号:
071010 ;
081704 ;
摘要:
Beta-amyloid is released into the brains of Alzheimer's patients, where it aggregates and causes damage to neurons. It is cleaved proteolytically from a large transmembrane glycoprotein amyloid precursor protein by a membrane-bound protease, known as beta-secretase identified previously as the acid protease, Asp-2. We have shown previously that beta-secretase is up-regulated by increased intracellular cholesterol, and down-regulated by cholesterol biosynthesis inhibition. Here we show using mass spectrometry that discrete changes in the glycosylation and palmitoylation of beta-secretase occur when cells expressing it are treated with statins.